+86-21-58356573
LANGUAGE

Company news

ImmuneOnco Biopharma Announced That The Third Bispecific Recombinant Protein Has Been Filed For Patent Application

2017-11-1 0:00:00Click:315

     On November 01 of 2017, ImmuneOnco Biopharma Co., Ltd., an emerging biotech company fully focusing on discovery and development of tumor immunotherapy, announced today that, the company’s third bispecific recombinant protein has been filed to the United States Patent and Trademark Office (USPTO) and has been accepted for patent invention (Application number: 62577704) on October 26 of 2017. 

     The patent disclosed a novel bispecific recombinant protein simultaneously binding to PD-L1 and CD47, which results in respective inhibition of PD-1/PD-L1 and CD47/SIRPa interaction. The final outcome of the inhibition is the restore of T lymphocyte as well as macrophage’s activation. In addition, through the Fc-FcgRs interaction, NK cells as well as macrophages can be actively activated to exert ADCC and ADCP activity.